WHO-GMP vs EU-GMP: What Pharma Exporters Need to Know

For Indian pharmaceutical companies looking at export markets, Good Manufacturing Practice certification is the first question every buyer asks. Two of the most common frameworks are WHO-GMP and EU-GMP. Both set out how medicines should be produced and controlled, yet the markets they unlock, the depth of inspection and the investment they require are quite different.

Choosing between them, or deciding when to move from one to the other, is a strategic decision that affects capital spending, product selection and sales plans for years. This guide explains what each framework covers, how they differ in practice and how to build a realistic certification roadmap.

What WHO-GMP Covers

WHO-GMP guidelines are published by the World Health Organization and are widely accepted across Africa, Southeast Asia, Latin America and CIS countries. In India, WHO-GMP certification is granted under the WHO certification scheme through the national and state regulators after a site inspection. It is often the minimum expectation for tender supply and product registration in emerging markets.

• Recognised by many ministries of health and procurement agencies
• Focus on documentation, quality control, hygiene and basic validation
• Achievable for most well run facilities with targeted upgrades
• Supports issue of a Certificate of Pharmaceutical Product for exports

For many Indian manufacturers, WHO-GMP is the natural first step beyond the domestic Schedule M requirements. It formalises quality systems, strengthens documentation and gives international buyers confidence to begin supplier qualification.

What EU-GMP Adds

EU-GMP is the standard enforced by European regulators and is closely aligned with PIC/S. It places much greater emphasis on facility design, contamination control, data integrity, validation and a mature pharmaceutical quality system. Sites that pass an EU inspection are often viewed favourably by regulators in other highly regulated markets as well.

In practical terms, EU-GMP inspectors look well beyond whether procedures exist. They examine whether the quality system actually works: how deviations are investigated, whether CAPAs are effective, how risks are assessed, how suppliers are qualified and whether electronic data is protected with audit trails and controlled access.

EU-GMP is less a certificate and more a culture. Facilities that succeed treat it as a continuous way of working rather than a one time audit.

Key Differences at a Glance

Area	WHO-GMP	EU-GMP
Typical markets	Africa, Asia, LATAM, CIS	European Union and PIC/S aligned markets
Inspection depth	Moderate	Very detailed, risk based
Data integrity focus	Growing	Central requirement
Facility and HVAC design	Basic GMP zoning	Strict segregation, pressure cascades, monitoring
Qualified Person release	Not required	Batch certification by a QP in the EU
Upgrade investment	Lower	Significantly higher

The Business Case for Each Path

WHO-GMP makes sense when your priority markets are emerging economies where price competitiveness and reliable supply matter most. The investment is moderate and the payback can be quick if you already have products and distribution partners lined up.

EU-GMP makes sense when you want to supply regulated markets, partner with multinational companies for contract manufacturing, or position your brand at the premium end of emerging markets. Margins are usually higher, but so are the costs of facility upgrades, validation, staffing and ongoing compliance.

Some companies choose a hybrid approach: one block or line is upgraded to EU-GMP for regulated market products, while other blocks remain WHO-GMP for emerging market supply. This protects capital while opening premium opportunities.

Common Gaps Found When Moving to EU-GMP

• HVAC systems without adequate pressure differentials or monitoring
• Laboratory systems without audit trails or with shared logins
• Weak deviation investigations that stop at “human error”
• Incomplete cleaning validation for shared equipment
• Supplier qualification based only on certificates, without audits
• Limited trending of quality data such as complaints and out of trend results

How to Choose Your Path

1. Map your priority export markets for the next three to five years.
2. Run a gap assessment of your facility against both frameworks.
3. Estimate the capex, staffing and timeline for each upgrade route.
4. Identify products whose margins can justify the higher compliance cost.
5. Plan a phased approach, starting with WHO-GMP and building towards EU-GMP where the business case supports it.

Preparing for the Inspection Itself

Whichever framework you pursue, inspection readiness depends on consistent daily practice rather than last minute preparation. Run internal audits against the target guideline, hold mock inspections led by experienced auditors, and make sure every department head can explain their processes, records and recent deviations confidently. Close previous observations with documented evidence of effectiveness, not just completed paperwork.

People and Culture Make the Difference

Facilities and documents can be upgraded with investment, but inspections are ultimately passed by people. Build training programmes that explain why each requirement exists, encourage staff to report problems early and make quality a shared responsibility rather than a department. Leadership visibility on the shop floor and in quality reviews sends a strong signal that compliance matters.

Budgeting for Ongoing Compliance

Certification is not a one time cost. Plan annual budgets for requalification of equipment and utilities, calibration, environmental monitoring, training, internal and external audits, and upgrades to laboratory systems. EU-GMP sites also need sufficient quality staff to manage deviations, change controls, product quality reviews and supplier audits in depth. Companies that underfund these activities after certification often struggle at the next inspection.

A realistic compliance budget protects the certification that took years to earn and keeps export markets open.

Questions to Ask Before You Invest

• Which specific customers or markets require EU-GMP, and what volumes do they offer?
• Can a dedicated block or line meet the requirement instead of the whole site?
• Do we have, or can we hire, the quality leadership needed to sustain EU-GMP?
• How will the upgrade affect current production and supply commitments?

Clear answers turn certification from an aspiration into a funded, scheduled project.

It also helps to speak with companies that have already made the journey. Their experience with timelines, consultants, inspection style and post certification workload gives a realistic picture that no guideline can provide, and often reveals practical shortcuts and pitfalls worth knowing in advance.

Need help assessing your facility? The Zanax Healthcare regulatory and turnkey teams can carry out a detailed gap analysis and build a realistic, phased upgrade roadmap for your site.